815619-12-6
815619-12-6 structure
- Name: NTU281
- Chemical Name: NTU281
- CAS Number: 815619-12-6
- Molecular Formula: C25H31N2O6S+
- Molecular Weight: 487.59
- Catalog: Signaling Pathways Apoptosis Apoptosis
- Create Date: 2022-09-19 09:22:04
- Modify Date: 2024-09-11 18:46:48
-
NTU281 is a potent transglutaminase-2 inhibitor. NTU281 can reduce the increases in serum creatinine and albuminuria in diabetic rats. NTU281 can also reduce glomerular collagen I accumulation, Hic-5 and α-SMA expression, and apoptosis. NTU281 can be used for researching glomerulosclerosis caused by diabetes[1][2].
| Name | NTU281 |
|---|
| Description | NTU281 is a potent transglutaminase-2 inhibitor. NTU281 can reduce the increases in serum creatinine and albuminuria in diabetic rats. NTU281 can also reduce glomerular collagen I accumulation, Hic-5 and α-SMA expression, and apoptosis. NTU281 can be used for researching glomerulosclerosis caused by diabetes[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | NTU281 (2.5 μl/h of 50 mM; cannulate to deliver into kidneys) reduces glomerular collagen I overexpression as well as the increases in glomerular Hic-5 and α-SMA expression; also decreases serum creatinine, albuminuria, glomerulosclerosis and tubulointerstitial scarring in diabetic rats[1][2]. Animal Model: Male Wistar Han rats [subjected to right uninephrectomy, then induced hyperglycemia by tail vein injection of streptozotocin (35 mg/kg in citrate buffer pH 4)][1] Dosage: 2.5 μl/h of 50 mM Administration: Cannulated to deliver into kidneys Result: Reduced glomerular collagen I overexpression by ~50%; reduced the increases in glomerular Hic-5 expression; reduced diabetic nephropathy-induced α-SMA expression. Animal Model: Male Wistar Han rats [subjected to right uninephrectomy, then induced hyperglycemia by tail vein injection of streptozotocin (35 mg/kg in citrate buffer pH 4)][2] Dosage: Various concentration Administration: Cannulated to deliver into kidneys Result: Significantly reduced the increases in serum creatinine (-68%) and albuminuria (-80%) in diabetic rats during eight-month experimental period; reduced in glomerulosclerosis (-76.6%) and tubulointerstitial scarring (-68.2%) as a result of lowered accumulation of collagen I, III and IV; and reduced numbers of myofibroblasts present. |
| References |
| Molecular Formula | C25H31N2O6S+ |
|---|---|
| Molecular Weight | 487.59 |